Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: tonyt who wrote (27911)	2/6/1999 9:45:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Your speculation was certainly unreasonable by anyone familiar with the FDA approval process. The likelihood that there was a "problem with the drug" after an "approvable letter" had been received and the outstanding issues had been described in a press release and conference call (the outstanding issues were the wording on the label and the data supporting an expiration date), and the advisory committee had voted 8-1 for approval, was absurd at best and intentionally misleading at worst.